Source:http://linkedlifedata.com/resource/pubmed/id/15209190
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2004-6-22
|
pubmed:abstractText |
The field of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma (NHL) has advanced significantly over the past decade, and several radioimmunoconjugates are being tested in clinical trials. Two of these antibodies target CD20: yttrium-90 (Y-90)-labeled ibritumomab tiuxetan (Zevalin) and tositumomab/iodine-131 (I-131)-labeled tositumomab (Bexxar). Other agents target either CD22 (Y-90 epratuzumab) or human leukocyte antigen (HLA)-DR (I-131 Lym-1), respectively. In February 2002, Y-90-labeled ibritumomab tiuxetan became the first radioimmunoconjugate to be approved by the US Food and Drug Administration (FDA) for the treatment of cancer. Tositumomab/I-131 tositumomab was approved in June 2003. Thus, two radioimmunoconjugates have been approved for the treatment of NHL. Both agents, when administered as a single dose, have produced impressive tumor response rates with an acceptable toxicity profile. The main side effect is reversible myelosuppression. Radioimmunotherapy produces overall response rates of approximately 80% in patients with low-grade lymphomas, and 25% to 30% of patients achieve a complete remission. Lower response rates (approximately 40%) have been reported in patients with large-cell lymphomas. This review discusses the clinical trials of radioimmunotherapeutic agents for NHL that demonstrated their safety and efficacy and outlines the current status of these agents.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD20,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Iodine Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Yttrium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/ibritumomab tiuxetan
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0890-9091
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
623-30; discussion 633-4, 637-8, 640
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15209190-Antibodies, Monoclonal,
pubmed-meshheading:15209190-Antigens, CD20,
pubmed-meshheading:15209190-Antineoplastic Agents,
pubmed-meshheading:15209190-Clinical Trials as Topic,
pubmed-meshheading:15209190-Humans,
pubmed-meshheading:15209190-Iodine Radioisotopes,
pubmed-meshheading:15209190-Lymphoma, B-Cell,
pubmed-meshheading:15209190-Radioimmunotherapy,
pubmed-meshheading:15209190-Yttrium Radioisotopes
|
pubmed:year |
2004
|
pubmed:articleTitle |
Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
|
pubmed:affiliation |
Mayo College of Medicine, Rochester, Minnesota 55905, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Review
|